SPOTLIGHT -
Orlando, FL-Among men with prostate cancer, declines in mortality and hospitalization have exceeded those in cardiovascular and other competing diseases, and most deaths among prostate cancer patients are now due to non-prostate cancer causes.
Multicomponent intervention linked with improved QOL in patients with OAB
In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
SBRT shows tolerability in high-risk and recurrent prostate cancer
Treatment with SBRT showed a minimal effect on prostate cancer-specific HRQL measures in regard to urinary incontinence domain scores, urinary irritative/obstructive domain scores, and bowel domain scores.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
First patient dosed with TLX250-CDx in Italy for ccRCC
With the dosing of the first patient in Italy, Telix’s expanded access program for TLX250-CDx in ccRCC now includes 3 active countries, including the Netherlands and the US.
FDA grants orphan drug designation to ADV7103 for cystinuria
ADV7103 is currently being studied in the phase 2/3 CORAL-1 study, enrolling patients with cystinuria across centers in France and Belgium.